VRTX:NSD-Vertex Pharmaceuticals Incorporated (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 207.15

Change

-4.43 (-2.09)%

Market Cap

USD 55.11B

Volume

2.06M

Average Target Price

USD 298.11 (+43.91%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-10-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals, Inc

+5.93 (+1.02%)

USD61.69B 22.47 17.37
SGEN Seagen Inc

-1.09 (-0.55%)

USD34.26B N/A N/A
MRNA Moderna, Inc

-0.29 (-0.41%)

USD27.83B N/A N/A
BGNE BeiGene, Ltd

+2.28 (+0.76%)

USD27.09B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

-0.85 (-0.70%)

USD26.65B 32.43 29.34
RPRX Royalty Pharma plc

-0.24 (-0.62%)

USD23.68B 33.93 9.28
GMAB Genmab A/S

-0.70 (-1.96%)

USD22.98B 25.74 2.86
BNTX BioNTech SE

-5.76 (-6.49%)

USD21.12B -99,999.99 N/A
IMMU Immunomedics, Inc

-78.93 (-89.83%)

USD20.31B N/A N/A
INCY Incyte Corporation

+0.75 (+0.84%)

USD19.62B 47.64 35.20

ETFs Containing VRTX

Symbol Name Weight Mer Price(Change) Market Cap
BBH VanEck Vectors Biotech ET.. 0.00 % 0.35 %

-2.44 (-1.53%)

USD0.49B
XMU:CA iShares MSCI Min Vol USA .. 0.00 % 0.30 %

-0.62 (-1.07%)

USD0.44B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.06 (-1.11%)

N/A
XMVU:LSE Xtrackers MSCI USA Minimu.. 0.00 % 0.20 %

-0.65 (-1.57%)

USD4.46M
VLIQ:LSE Vanguard Global Liquidity.. 0.00 % 0.00 %

-0.47 (-1.67%)

USD0.01B
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

-0.07 (-1.08%)

USD0.19B
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

-0.04 (-0.85%)

USD0.19B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

-0.08 (-1.25%)

USD0.07B
HWF:CA Middlefield Health & Well.. 0.00 % 0.85 %

-0.04 (-0.33%)

USD0.05B
ACZ:CA Middlefield American Core.. 0.00 % 0.75 %

N/A

USD0.01B
LS:CA Middlefield Healthcare & .. 0.00 % 0.85 %

-0.02 (-0.19%)

USD0.08B
QGRO American Century U.S. Qua.. 0.00 % 0.29 %

-0.81 (-1.43%)

USD0.21B
CACG ClearBridge All Cap Growt.. 0.00 % 0.54 %

-0.87 (-2.14%)

USD0.19B
ZBIO ProShares UltraPro Short .. 0.00 % 0.95 %

N/A

USD2.51M
XMS:CA iShares MSCI Min Vol USA .. 0.00 % 0.30 %

-0.43 (-1.51%)

USD0.06B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

-1.37 (-1.94%)

USD0.21B
VLQ:CA Vanguard Global Liquidity.. 0.00 % 0.37 %

N/A

USD0.01B
UBIO ProShares UltraPro Nasdaq.. 0.00 % 0.95 %

N/A

USD0.02B
RYH Invesco S&P 500 Equal Wei.. 0.00 % 0.40 %

-3.35 (-1.36%)

USD0.71B
RPG Invesco S&P 500 Pure Grow.. 0.00 % 0.35 %

-3.12 (-2.11%)

USD2.49B
PWC Invesco Dynamic Market ET.. 0.00 % 0.59 %

-1.74 (-1.80%)

USD0.12B
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

-0.51 (-0.86%)

USD0.22B
LABD Direxion Daily S&P Biotec.. 0.00 % 1.06 %

+1.83 (+3.78%)

USD0.08B
KNOW Direxion All Cap Insider .. 0.00 % 0.66 %

-20.00 (-7.58%)

USD0.05B
IBB iShares Nasdaq Biotechnol.. 0.00 % 0.47 %

-1.38 (-1.01%)

USD9.52B
FHH:CA FT AlphaDEX U.S. Health C.. 0.00 % 0.70 %

-0.01 (-0.03%)

USD0.01B
DEF Invesco Defensive Equity .. 0.00 % 0.55 %

-0.73 (-1.29%)

USD0.31B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

+0.57 (+1.89%)

USD0.01B
VLIQ:XETRA Vanguard Global Liquidity.. 0.00 % 0.00 %

-0.60 (-1.94%)

USD0.01B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.39% 49% F 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.39% 49% F 48% F
Trailing 12 Months  
Capital Gain 6.77% 44% F 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.77% 44% F 59% F
Trailing 5 Years  
Capital Gain 72.48% 80% B- 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 72.48% 80% B- 73% C
Average Annual (5 Year Horizon)  
Capital Gain 29.42% N/A N/A 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 29.42% N/A N/A 84% B
Risk Return Profile  
Volatility (Standard Deviation) 32.53% N/A N/A 43% F
Risk Adjusted Return 90.43% N/A N/A 90% A-
Market Capitalization 55.11B 100% A+ 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 26.75 30% F 37% F
Price/Book Ratio 7.33 27% F 19% F
Price / Cash Flow Ratio 35.12 3% F 9% F
EV/EBITDA 20.98 20% F 36% F
Management Effectiveness  
Return on Equity 33.06% 98% A+ 96% A
Return on Invested Capital 17.68% 92% A- 90% A-
Return on Assets 15.25% 98% A+ 98% A+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 2.55 64% D 57% F
Short Percent 1.30% 89% B+ 73% C
Beta 0.79 79% C+ 71% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.